Insights / Case Studies
Keep up with Primrose Bio’s
Case studies
Fab Antibody Fragment Titer Improvement
A partner was developing a Fab fragment to quickly neutralize a therapeutic substrate.
Multimeric VHH Nanobody Expression
VHH single domain antibodies readily express in the Pfenex Expression Technology®.
Rapid Assessment of Fab-VHH Expression Application of the Pfast™ Program for Early-Stage Titer and Activity Screening
Development of a bi-specific antibody derivative: a Fab–VHH fusion.
Pfast™ Lead Identification and Optimization Supporting Computational Drug Discovery Technology
AI generated, humanized Fab from partner
required production and binding assessment.
Development of an Oncology VHH-ADC Candidate via Site-Specific Non-Canonical Amino Acid Conjugation
Incorporate a non-canonical amino acid (ncAA) pAzF, into a VHH antibody for ADC enhancement, PET771.
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.
Fusion-Enabled Biosimilar Peptide Teriparatide Expression
Teriparatide, a recombinant PTH (1-34) fragment used in osteoporosis therapy, is a short peptide that can be difficult to express and recover efficiently.
Production of disulfide-rich cow knob domain antibodies: Picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
Comparable Immunogenicity Observed in Peptides Coupled to PeliCRM197 and KLH in a Murine Model
In this case study, 3 peptides directed to one therapeutic target were conjugated to either CRM197 produced with Pfenex Expression Technology®.
Anti-IL-4 Conjugate Vaccine Prepared with PeliCRM197 is More Immunogenic than KLH Analog
Anti-interleukin 4 (IL-4) conjugate vaccines consist of IL-4 chemically coupled to a carrier protein.
